Professional Essentials · Free · No registration
Crystal-induced Arthritis
Gout, CPPD and basic calcium phosphate disease: preserving the infection differential, choosing treatment and measuring meaningful recovery.
1. Begin with the hot joint
A new swollen, painful joint needs an explanation even when gout or CPPD is already on the problem list. Monosodium urate, calcium pyrophosphate and basic calcium phosphate produce different syndromes and require different long-term strategies. First distinguish acute synovitis from periarticular pain, persistent inflammatory arthritis and established structural damage.
Infection remains the first safety question. Assess systemic illness, recent procedures, skin infection, prosthetic material and immunosuppression. Fever may be absent. Following the SANJO guideline, aspirate promptly when septic arthritis is suspected and send microbiology, cell count with differential and crystal analysis; prioritize bacterial identification if fluid is scarce. Obtain blood cultures when indicated. Sample before antibiotics when feasible in a stable patient, but do not delay treatment for sepsis or shock.
Neither crystals nor a negative Gram stain establishes sterility. A low synovial leukocyte count or reassuring serum inflammatory marker cannot independently exclude infection. Avoid intra-articular glucocorticoid while infection remains a meaningful possibility. Worsening symptoms or an unexpectedly poor response should reopen the differential rather than simply trigger more anti-inflammatory treatment.
The hot joint and infection assessment → Open demo · No registration
2. Identify deposits and their relevance
Serum urate is not a crystal test. Hyperuricemia can occur without gout, and a value during a flare may be misleadingly low. NICE NG219 advises repeating urate at least two weeks after the flare settles when suspicion remains. Record the basis of diagnosis before committing a patient to long-term treatment.
Compensated polarized microscopy can identify MSU and CPP crystals, although sparse material and examiner limitations can produce negative results. Routine microscopy does not reliably identify BCP. Describe which crystals were seen and retain the parallel microbiology assessment; a generic “crystal-positive” report is less useful.
The EULAR imaging recommendations support ultrasound or dual-energy CT for gout, radiographs or ultrasound for peripheral CPPD, and CT when axial CPP deposition is suspected. Characteristic imaging may confirm gout deposition without aspiration for that purpose, but cannot remove a separate indication to investigate infection. Correlate deposits with the symptomatic structure: an impressive image may reflect incidental deposition rather than today’s pain generator.
Imaging by clinical question → Professional access required
3. Control inflammation safely
For a gout flare, select colchicine, an NSAID or a glucocorticoid according to the patient rather than a fixed hierarchy. Kidney function, heart failure, bleeding risk, diabetes, current infection and interacting medicines may determine the safest option. An accessible monoarthritis can favor local treatment after infection has been assessed; widespread inflammation may require systemic treatment.
Colchicine needs particular medication reconciliation, including recent doses and renal or hepatic impairment. Strong CYP3A4 or P-glycoprotein inhibitors can markedly increase exposure; familiar drugs such as clarithromycin and cyclosporine can make an otherwise routine plan unsafe. Do not use diarrhea as a dosing target. NSAIDs and systemic glucocorticoids have their own organ-specific risks; several rescue drugs should not be layered automatically.
Relieving inflammation and lowering urate are separate tasks. Explain the purpose of each prescription and provide a written flare plan with limits and reassessment triggers. Established urate-lowering treatment is generally continued during an attack unless a separate adverse effect or contraindication requires interruption. Repeated rescue courses should prompt review of the long-term strategy.
Flare medicines and prescribing constraints → Professional access required
4. Treat gout to a sustained target
The 2020 ACR guideline strongly supports urate-lowering treatment for tophi, gout-related radiographic damage or at least two attacks yearly. Selected patients with less frequent disease also benefit from shared consideration. Allopurinol is the preferred initial drug, including in CKD, with a low starting dose and subsequent titration. ACR recommends a serum urate target below 6 mg/dL and anti-inflammatory prophylaxis for at least three to six months, with continuation when attacks persist.
Before starting allopurinol, assess whether HLA-B*58:01 testing is indicated; ACR conditionally recommends it for Southeast Asian ancestry, including Han Chinese, Korean or Thai ancestry, and African American patients. The prescribing information emphasizes hypersensitivity and important interactions. New rash requires stopping the drug and prompt assessment; severe systemic or mucosal features require urgent care.
Assign responsibility for urate checks and dose adjustment. NICE allows consideration of a target below 5 mg/dL in selected severe disease. Early attacks during urate lowering do not necessarily indicate failure. Before specialist escalation, distinguish inadequate titration, interrupted access, intolerance and persistent disease despite appropriate treatment.
Allopurinol and HLA-B*58:01 safety → Professional access required
5. Manage the CPPD phenotype
CPPD includes acute attacks, chronic arthritis, osteoarthritis with deposition and incidental chondrocalcinosis. EULAR diagnostic guidance identifies associations including hyperparathyroidism, hemochromatosis and hypomagnesemia. Earlier onset, family history or an atypical pattern warrants targeted evaluation. Treating an associated disorder has health value but should not be promised to dissolve established deposits.
Acute treatment uses aspiration and, where appropriate, local glucocorticoid, colchicine, an NSAID or systemic glucocorticoid. In hospitalized older adults, COLCHICORT found equivalent short-term pain relief with colchicine and prednisone, with different adverse-effect profiles. Its short endpoint does not establish one preferred regimen for every patient.
There is no established equivalent of gout’s deposit-clearing urate strategy. CPPD management guidance supports selected prophylaxis or chronic anti-inflammatory treatment; incidental asymptomatic deposition requires no treatment. Persistent synovitis needs reassessment for overlapping immune-mediated arthritis. Severe acute neck pain with peri-odontoid calcification can represent crowned dens syndrome, but infection, fracture and neurological emergencies must still be considered.
CPPD phenotypes and related chapters → Open demo · No registration
6. Measure recovery beyond the image
BCP-associated calcific tendinopathy is not gout and does not respond to a serum urate target. Match the deposit to symptoms, tendon function and examination before discussing intervention. A 2023 sham-controlled shoulder trial found no benefit of ultrasound-guided lavage with corticosteroid over sham treatment in its studied population. Discuss procedural uncertainty and alternatives; disappearance of calcium is not equivalent to functional recovery.
One patient may have gout, CPPD and osteoarthritis simultaneously. Track attacks, objective inflammation, structural limitation and medication toxicity separately. Review cardiometabolic disease and kidney health without promising that gout medication provides universal organ protection. Nutrition and sustainable weight management can support overall health; punitive dietary restrictions do not substitute for indicated urate lowering.
Agree on practical outcomes: walking, work, sleep, fewer attacks and less rescue medication. A dated monitoring plan, accessible prescriptions and clear instructions for an unusual flare are as important as choosing the initial drug.
At each review, ask what the patient actually takes and what prevents reliable use. Cost, confusing instructions and fear after an early attack are actionable problems. Distinguish the rapid goal of symptom relief from the slower goal of reducing MSU burden. If a patient remains symptomatic at target, reassess the duration of control and the source of each symptom before adding treatment. A target reached once does not establish sustained control.
Sources and clinical verification
Clinically reviewed on October 4, 2026.
- COLCRYS: US prescribing information.
- SANJO guideline for native-joint septic arthritis (2023).
- NICE NG219: Gout diagnosis and management (2022).
- EULAR imaging recommendations for crystal-induced arthropathies (2023; published 2024).
- ACR guideline for management of gout (2020).
- Allopurinol: US prescribing information, revised 2026.
- EULAR CPPD recommendations, part I: terminology and diagnosis (2011).
- Pascart et al. COLCHICORT randomized trial (2023).
- EULAR CPPD recommendations, part II: management (2011).
- Moosmayer et al. Lavage versus sham for calcific shoulder tendinopathy (2023).